Literature DB >> 729620

The pharmacokinetics of slow-release procainamide.

W J Tilstone, D H Lawson, W Campbell, I Hutton, T D Lawrie.   

Abstract

Procainamide was given to 20 patients with normal renal function as an i.v. bolus of 500 mg followed by 1.0 or 1.5 g eight-hourly by mouth in the form of a slow release preparation (Durules). 97.6 +/- 27.1 (SD)% of the oral procainamide was absorbed, the absorption half life being 1.54 h. The elimination half life following the oral formulation was 6.0 +/- 0.8 h, compared to a mean of 3.4 +/- 0.4 h following i.v. administration. Elimination half life following i.v. administration was slightly related to acetylator status, being 2.75 +/- 0.9 h in fast acetylators, and 4.4 +/- 2.4 h in slow acetylators. This dependence on acetylator status was not seen in half life following oral administration. Total body clearance, steady state plasma procainamide and N-acetylprocainamide were not significantly dependent on acetylator status, although a few patients who are slow acetylators had unexpectedly low clearance and high steady state procainamide concentrations when given the higher dose.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 729620     DOI: 10.1007/bf00560459

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  The pharmacokinetics of procainamide in normal subjects using a specific gas chromatographic assay.

Authors:  K J Simons; R H Levy; R E Cutler; G T Christopher; A Lindner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1975-06

2.  Metabolism of procainamide in normal and cardiac subjects.

Authors:  E G Giardina; J Dreyfuss; J T Bigger; J M Shaw; E C Schreiber
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

3.  Relationship between the pharmacokinetics and pharmacodynamics of procainamide.

Authors:  R L Galeazzi; L Z Benet; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

4.  Acetylator phenotype and the clinical pharmacology of slow-release procainamide.

Authors:  W Campbell; W J Tilstone; D H Lawson; I Hutton; T D Lawrie
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

5.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

6.  An improved and simplified method of detecting the acetylator phenotype.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1969-12       Impact factor: 6.318

7.  Determination of procainamide acetylator status.

Authors:  J J Lima; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1978-01       Impact factor: 6.875

8.  Adverse reactions to procainamide.

Authors:  D H Lawson; H Jick
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

9.  Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets.

Authors:  C Graffner; G Johnsson; J Sjögren
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

10.  Capacity-limited elimination of procainamide in man.

Authors:  W J Tilstone; D H Lawson
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1978-08
  10 in total
  2 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.

Authors:  P Ylitalo; R Ruosteenoja; O Leskinen; T Metsä-Ketelä
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.